NEW YORK, July 21 American OrientalBioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceuticalcompany dedicated to improving health through the development, manufacture andcommercialization of a broad range of prescription and over the counter ("OTC")products in China, today announced that AOBO was honorably elected as one ofthe "Top 20 Most Competitive Public Pharmaceutical Companies in China." Thisevent was jointly organized by China's leading healthcare industryassociations, including the Chinese Pharmaceutical Enterprise Association andits publication, Healthcare Executive Magazine, and China's Center forPharmaco-economics and Outcomes Research (CCPOR) at Beijing University, wherean awards ceremony was held today.
The 20 listed companies were selected from 132 Chinese pharmaceuticalcompanies listed in Shanghai, Shenzhen, Hong Kong, Singapore, New York or onNASDAQ, as of February of this year. The selection criteria were based on thecompanies' management capabilities, brand recognition, financial strength,resource accessibility and quality of key team members.
Mr. Tony Liu, Chairman and Chief Executive Officer of American OrientalBioengineering, commented, "We are very honored to receive this recognition bythe industry. This award speaks to the strength of our brand value andcompetitiveness in the changing environment. We will continue to focus oncreating greater value for investors."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a China-based pharmaceuticalcompany dedicated to improving health through the development, manufacture andcommercialization of a broad range of prescription and over the counterproducts.
Statements made in this press release are forward-looking and are madepursuant to the safe harbor provisions of the Securities Litigation Reform Actof 1995. Such statements involve risks and uncertainties that may causeactual results to differ materially from those set forth in these statements.The economic, competitive, governmental, technological and other factorsidentified in the Company's filings with the Securities and ExchangeCommission, including the Form 10-K for the year ended December 31, 2008, maycause actual results or events to differ materially from those described inthe forward looking statements in this press release. The Company undertakesno obligation to publicly update or revise any forward-looking statements,whether because of new information, future events, or otherwise.
SOURCE American Oriental Bioengineering, Inc.